Avalo Therapeutics Inc
$ 14.70
-4.55%
18 Jun - close price
- Market Cap 772,714,000 USD
- Current Price $ 14.70
- High / Low $ 15.93 / 14.59
- Stock P/E N/A
- Book Value 2.77
- EPS -5.57
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.89 %
- 52 Week High 24.27
- 52 Week Low 4.50
About
Avalo Therapeutics Inc is a clinical-stage biotechnology company dedicated to innovating therapies for rare and underserved diseases, particularly in the realm of immunological regulation. The company boasts a strong pipeline of proprietary drug candidates that target serious conditions characterized by significant unmet medical needs, underscoring its commitment to advancing healthcare solutions. Leveraging its extensive expertise in disease mechanisms and thorough clinical trial methodologies, Avalo is strategically positioned to develop transformative therapies. By maintaining a strong focus on patient-centric approaches, Avalo aims to enhance therapeutic outcomes and create meaningful changes in patients' lives, reflecting its potential to make a profound impact in the biopharmaceutical sector.
Analyst Target Price
$45.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-23 | 2025-11-06 | 2025-08-07 | 2025-04-04 | 2025-03-27 | 2024-11-07 | 2024-07-11 | 2024-05-13 | 2024-03-28 | 2023-11-09 | 2023-08-03 |
| Reported EPS | -0.98 | -0.37 | -2.19 | -1.92 | -1.2867 | -2.74 | -1.25 | -14.07 | -141 | -116.21 | -0.11 | -0.59 |
| Estimated EPS | -1.0717 | -1.495 | -1.22 | -1.43 | -1.605 | 1.665 | -1.19 | -6.7 | -1.18 | -4.8 | -1.1 | -0.8 |
| Surprise | 0.0917 | 1.125 | -0.97 | -0.49 | 0.3183 | -4.405 | -0.06 | -7.37 | -139.82 | -111.41 | 0.99 | 0.21 |
| Surprise Percentage | 8.5565% | 75.2508% | -79.5082% | -34.2657% | 19.8318% | -264.5646% | -5.042% | -110% | -11849.1525% | -2321.0417% | 90% | 26.25% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.68 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVTX
2026-06-16 11:40:11
Avalo Therapeutics announced its plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027. This new engineered anti-IL-1β monoclonal antibody is designed for extended dosing intervals and will be developed for hidradenitis suppurativa and other inflammatory disorders. The company's positive progress with its lead asset, abdakibart, and recent financing efforts have contributed to a strong financial position, with analysts bullish on its stock.
2026-06-16 11:39:27
Avalo Therapeutics has announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody intended for hidradenitis suppurativa (HS) and other inflammatory disorders. The company plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027, aiming for extended dosing intervals to improve patient convenience and adherence. This progression follows recent financing and positive Phase 2 data for their abdakibart program.
2026-06-16 11:39:27
Avalo Therapeutics plans to submit an Investigational New Drug application for AVTX-010, an engineered anti-IL-1β monoclonal antibody, in the first half of 2027. The company intends to develop AVTX-010 for hidradenitis suppurativa and other inflammatory disorders, building on the success of its lead asset, abdakibart. Avalo Therapeutics' shares have performed strongly, and analysts maintain bullish price targets, supported by a recent financing round and a strong balance sheet.
2026-06-16 10:39:27
Avalo Therapeutics is expanding its pipeline with AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody engineered for extended dosing intervals. This new candidate is intended for hidradenitis suppurativa and other inflammatory diseases, building on the success of its lead asset, abdakibart. An Investigational New Drug (IND) application for AVTX-010 is planned for the first half of 2027.
2026-06-16 10:39:27
Avalo Therapeutics is expanding its pipeline with AVTX-010, a long-acting, next-generation anti-IL-1β monoclonal antibody, building on the success of its existing asset, abdakibart. This new molecule is designed for less frequent dosing, aiming to improve patient convenience and adherence in chronic inflammatory diseases like hidradenitis suppurativa (HS). The company plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027.
2026-06-16 07:00:00
Avalo Therapeutics is expanding its pipeline with AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, building on the success of its abdakibart program. This new molecule is designed for less frequent dosing, aiming to improve patient convenience and adherence in treating hidradenitis suppurativa and other inflammatory disorders. An Investigational New Drug (IND) application for AVTX-010 is planned for the first half of 2027.
